Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 Pretax Margin % is -207.68% as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, SL Science Holding ranks worse than 57.94% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
SL Science Holding Pretax Margin % Related Terms
SL Science Holding Pretax Margin % Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Pretax Margin % Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Pretax Margin %
60.64
-33.71
-173.87
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Pretax Margin %
0.00
-38.59
-30.92
-141.90
-207.68
SLBT vs DMRA, BCAX, TYRA: Pretax Margin % Comparison
For the Biotechnology subindustry, SL Science Holding's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where SL Science Holding's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding (SLBT) has a Pretax Margin % of -207.68% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SL Science Holding and its competitors. According to the industry distribution chart, SL Science Holding ranks #547 out of 944 companies in the Biotechnology industry, placing it in the top 57.9%.
Is SL Science Holding's Pretax Margin % too high?
SL Science Holding's current Pretax Margin % is -207.68%. Based on the distribution chart, SL Science Holding ranks #547 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Pretax Margin % compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #547 out of 944 companies for Pretax Margin %. This places SL Science Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SL Science Holding and its competitors. SL Science Holding's current Pretax Margin % is -207.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Pretax Margin % of -207.68%. The current Pretax Margin % is -207.68%. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Pretax Margin % is -207.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
